Skip to main
ADUS

Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare (ADUS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Addus HomeCare is actively investing in technology to improve their services, with the implementation of their next-generation Homecare Homebase (HCHB) platform and caregiver app rollout. The personal care segment has shown consistent organic growth, driven by improved caregiver utilization and scheduling. However, changes in personal care policies and federal regulations could potentially impact their financials. The hospice segment also showed strong organic census growth, but Home Health revenues were below expectations due to lower volumes. Overall, Addus HomeCare is a well-positioned company with a positive outlook for the future, especially if they can successfully integrate their recent acquisition of Gentiva.

Bears say

Addus HomeCare is likely to face challenges in its Personal Care segment as a potential repeal of the 80/20 Medicaid Access rule could negatively impact its access to care and result in lower revenues. The company's recent decline in M&A activity may also hinder its growth potential, despite its strong financial position. Furthermore, potential Medicare moratoriums on new agency enrollment and labor constraints may continue to dampen growth and hinder the company's ability to achieve its target price.

Addus HomeCare (ADUS) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Addus HomeCare (ADUS) Forecast

Analysts have given Addus HomeCare (ADUS) a Buy based on their latest research and market trends.

According to 7 analysts, Addus HomeCare (ADUS) has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $130.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $130.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Addus HomeCare (ADUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.